KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Deferred Charges (2017 - 2018)

Biomarin Pharmaceutical's Amortization - Deferred Charges history spans 5 years, with the latest figure at $1.0 million for Q2 2018.

  • For the quarter ending Q2 2018, Amortization - Deferred Charges rose 13.54% year-over-year to $1.0 million, compared with a TTM value of $3.5 million through Jun 2018, up 170.9%, and an annual FY2018 reading of $3.6 million, down 3.09% over the prior year.
  • Amortization - Deferred Charges for Q2 2018 was $1.0 million at Biomarin Pharmaceutical, up from $886000.0 in the prior quarter.
  • The five-year high for Amortization - Deferred Charges was $1.0 million in Q2 2018, with the low at -$1.2 million in Q4 2014.
  • Average Amortization - Deferred Charges over 4 years is $523333.3, with a median of $825500.0 recorded in 2014.
  • Biggest YoY gain for Amortization - Deferred Charges was 1214.29% in 2014; the steepest drop was 2654.17% in 2014.
  • Tracing BMRN's Amortization - Deferred Charges over 4 years: stood at -$1.2 million in 2014, then skyrocketed by 167.13% to $823000.0 in 2015, then increased by 7.65% to $886000.0 in 2017, then rose by 13.54% to $1.0 million in 2018.
  • Per Business Quant, the three most recent readings for BMRN's Amortization - Deferred Charges are $1.0 million (Q2 2018), $886000.0 (Q2 2017), and $823000.0 (Q4 2015).